The 5 Best Earnings Trends of the Week
While this earnings season may be written off due to the pandemic, the fundamentals still matter as a measure for how companies survived the crisis. 24/7 Wall St. has taken a look at a…
All Work
Chris Lange
Are Record Intel Q2 Revenues Falling Short For Investors?
Chipmaker Intel reported second-quarter earnings per share of $1.23 and $19.73 billion in revenue, compared with consensus estimates that called for earnings of $1.11 per share and $18.55 billion in revenue.
This Analyst Sees Much More Upside for Chipotle After Earnings
Chipotle Mexican Grill has fared better during the pandemic than the rest of the industry. With shares just below all-time highs, it is understandable that some investors may be wary, but analysts only seem…
Milestone Pharma’s Next Big Move After FDA Nod
Milestone Pharmaceuticals shares more than doubled on Thursday after the company announced a key clinical and regulatory update.
Twitter’s Net Loss Can’t Hold Back Record Quarter
Twitter reported disappointing second-quarter financial results despite strong user growth on Thursday before the opening bell.
Why Tesla’s Q2 Is So Shocking
After markets closed Wednesday, electric vehicle maker Tesla reported $2.18 in earnings per share (EPS) and $6.04 billion in revenue, compared with consensus estimates that called for $0.03 in EPS and $5.23 billion in…
Microsoft Q4 Beat Doesn’t Move Investors
After markets closed Wednesday, Microsoft reported $1.46 in earnings per share (EPS) and $38.0 billion in revenue, compared with consensus estimates calling for $1.37 in EPS and $36.5 billion in revenue.
Best Buy Might Be Immune From the Amazon Threat
In the e-commerce era, when brick-and-mortar retailers by and large are failing, Best Buy is making a name for itself.
Pershing Square Tontine Finally Comes Public
Bill Ackman’s Pershing Square Tontine special purpose acquisition company entered the market on Tuesday above its original pricing.
Pfizer and BioNTech Set to Receive a Sweet Payoff for COVID-19 Vaccines
Pfizer and BioNTech S.E. aim to begin delivering 300 million doses of their vaccine for COVID-19 in 2021, but in the meantime, these companies will get a nice payoff.
United Airline’s Quarter: Less Crash More Burn
United Airlines reported a second-quarter net loss of $5.79 per share and $1.48 billion in revenue, compared with consensus estimates that called for a net loss of $9.02 in EPS and $1.32 billion in…
Snap Gets the Picture in Q2 But Investors Not Happy
Social media company Snap reported a second-quarter net loss of $0.09 per share and $454 million in revenue, compared with consensus estimates that called for a per-share loss of $0.09 and $438.09 million in…
Was Amazon Under Too Much Stress for Prime Day During the Pandemic?
Amazon.com is pushing back its much-lauded Prime Day due to the pandemic. Will this cause near-term pain for investors?
BioNTech Raises Over $400 Million to Boost COVID-19 Efforts
BioNTech is one of the leading companies in the race to a COVID-19 vaccine. With its shares up more than 160% year to date, it’s time to capitalize.
Late-Stage Diabetes Study Sets the Stage for Lexicon Pharma
Lexicon Pharmaceuticals shares surged on Tuesday after the company announced positive topline data for its late-stage studies in type 2 diabetes.
Moleculin Biotech’s Antimetabolites COVID-19 on Track for Treatment Status
Moleculin Biotech joins the ever-expanding list of coronavirus stocks as the company announced that a second round of independent laboratory testing has confirmed the antiviral activity of WP1122.
Why Immuron’s New COVID-19 Study Is a Game Changer
Immuron continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome due to the virus that causes COVID-19.
Declining Revenues Aren’t Enough to Hold IBM Back in Q2
IBM reported Monday after the markets closed that posted $2.18 in earnings per share (EPS) and $18.1 billion in revenue in the second quarter versus analysts' calls for $2.07 in EPS and $17.72 billion…
Why This FDA Clearance Is a Big Deal For Sorrento Therapeutics
Sorrento Therapeutics has announced that its treatment for COVID-19 had cleared its Phase 2 study in hospitalized patients with moderate to severe coronavirus infections.
Nikola Warrant Holders Must Be Happy With This
Nikola is in for an interesting trading week now that its warrants from its initial public offering have become exercisable.